NCT05556018

Brief Summary

Background Cardiac Resynchronization Therapy (CRT) is proven to improve survival and heart function of patient with certain electrical conduction abnormality and heart failure. However, in patient with certain electrical conduction abnormality, being nonresponder is observed in up to 40% in patient receiving CRT. Conventionally the surgical approach of CRT is to implant one pacing lead in the right heart and one in the left heart to resynchronize the contraction and the pacing lead in the left heart is usually placed in the posterior or lateral portion of the left heart. However, this single approach may not be optimal, especially for those patients with conduction abnormality known to have no response to CRT. Purpose of the clinical investigation The purpose of the Activation Pattern and Acute Hemodynamics of His and Left Bundle Pacing is to study the acute effect on the heart function and conduction abnormality of His and left bundle pacing in conventional CRT candidate. During CRT implantation, Hisbundle lead and Left bundle pacing lead will be placed and the acute effect on heart function will be studied by a wire placed in the left ventricle of the heart and the activation pattern will be studied by a noninvasive global mapping system. The pacing approach that optimally corrects conduction abnormality and improvement on the heart function acutely will be determined

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
27

participants targeted

Target at below P25 for not_applicable heart-failure

Timeline
Completed

Started Jul 2019

Longer than P75 for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 5, 2019

Completed
3.2 years until next milestone

First Submitted

Initial submission to the registry

September 16, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

September 27, 2022

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2024

Completed
Last Updated

February 16, 2024

Status Verified

February 1, 2024

Enrollment Period

4.5 years

First QC Date

September 16, 2022

Last Update Submit

February 15, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Improvement in myocardiac activation

    Correction of activation abnormality as evaluated by global noninvasive mapping system (ECGi) seen as an increase in acute dp/dt \> 5% from baseline with left bundle pacing comparing to biventricular pacing.

    6 months

Secondary Outcomes (14)

  • Procedure duration

    during procedure

  • Implantation success rate

    during procedure

  • Cine images and chest X ray

    6 months

  • Echocardiogram parameters: strain imaging

    6 months

  • Echocardiogram parameters: left ventricular systolic and diastolic volume

    6 months

  • +9 more secondary outcomes

Study Arms (1)

Tailor-made CRT delivery

EXPERIMENTAL

Cardiac resynchronization therapy given according to Electrical Activation Mapping result

Device: Electrical Activation Mapping Guided Cardiac resynchronization therapy

Interventions

To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation

Tailor-made CRT delivery

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult (aged 18 or above) of both sexes
  • Candidate for CRT therapy according to international guidelines.7
  • Informed consent by the patient
  • Already received stable dose of guideline directed medical therapy for at least 3 months

You may not qualify if:

  • Pregnant
  • Participating in another study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Chinese University of Hong Kong

Shatin, 999077, Hong Kong

RECRUITING

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Bryan Yan

    Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 16, 2022

First Posted

September 27, 2022

Study Start

July 5, 2019

Primary Completion

December 31, 2023

Study Completion

March 31, 2024

Last Updated

February 16, 2024

Record last verified: 2024-02

Locations